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New transplant approaches are urgently needed for patients with refractory severe aplastic anemia (SAA)
who lack a matched sibling or unrelated donor (UD) or who have failed UD or cord blood transplant. Patients
with refractory SAA are at risk of later clonal evolution to myelodysplastic syndrome and acute leukemia. We
report our pilot ﬁndings with haploidentical hematopoietic stem cell transplantation (haploHSCT) using
uniform reduced-intensity conditioning with postgraft high-dose cyclophosphamide in 8 patients with re-
fractory SAA or patients who rejected a prior UD or cord blood transplant. Six of 8 patients engrafted. Graft
failure was associated with donor-directed HLA antibodies, despite intensive pre-HSCT desensitization with
plasma exchange and rituximab. There was only 1 case of grade II skin graft-versus-host disease. We show
that haploHSCT can successfully rescue refractory SAA patients who lack donor-directed HLA antibodies but
not in the presence of donor-directed HLA antibodies. This novel protocol for haploHSCT for SAA has been
adopted by the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working
Party for a future noninterventional, observational study to further evaluate its efﬁcacy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients with severe aplastic anemia (SAA) who lack a
matched sibling or unrelated donor (UD) and who fail to
respond to immunosuppressive therapy are at increased risk
of death from infection and hemorrhage and later clonal
evolution to myelodysplastic syndrome and acute myeloid
leukemia. Risk factors for myelodysplastic syndrome/acute
myeloid leukemia include olderage, short telomeres, presence
of monosomy 7, prolonged use of granulocyte colony-
stimulating factor (G-CSF), and multiple courses of immuno-
suppressive therapy [1-5]. Hence, there is a need to explore
alternative donor hematopoietic stem cell transplantation
(HSCT) using either a haploidentical family donor [6-12] or
cord blood [13,14], because this is a potentially curative option.
However, most studies report poor outcomes, due to poor
engraftment, and high risk of graft-versus-host disease
(GVHD) with haploidentical HSCT (haploHSCT). Attractions
of haploHSCT are graft availability for most patients, lessdgments on page 1715.
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14.06.028expensive procedural cost than cordHSCT, and shorter time to
procurement of the graft. However, published data are limited
and mostly restricted to children and young adults [7-11].
Post-transplant cyclophosphamide (CY) has been used in
haploHSCT for hematological malignancies to selectively
deplete donor alloreactive T cells and thereby reduce acute
GVHD [15,16]. In the setting of aplastic anemia, high-dose
CY without stem cell support can salvage a signiﬁcant
proportion of refractory patients, but this approach has not
been met with widespread enthusiasm because of pro-
longed pancytopenia after therapy [17]. A nonmyeloablative
regimen with postgraft CY was reported in 2 patients with
hemolytic paroxysmal nocturnal hemoglobinuria and 1 with
both paroxysmal nocturnal hemoglobinuria and sickle cell
disease, resulting in sustained engraftment and absence of
GVHD in 2 patients [11]. In 2011, Dezern et al. [18] reported
the ﬁrst use of post-transplant CY for GVHD prophylaxis in
2 high-risk SAA patients. They used matched sibling
donors and myeloablative conditioning, with both patients
engrafting and no GVHD [18]. The Hopkins group also re-
ported 17 cases using the mini-haploidentical approach
with post-transplant CY in sickle cell disease. There were no
cases of mortality or GVHD, but primary graft failure was a
problem [19].Transplantation.
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using reduced-intensity conditioning with post-transplant
CY for haploHSCT in 8 SAA patients, 4 with refractory SAA
and 4 after failed UD or cord blood HSCT. We also used G-CSF
mobilized peripheral blood stem cells (PBSCs) instead of
bone marrow (BM) to achieve a high dose of infused CD34þ
cells for engraftment.
METHODS
Eight patients were transplanted, 4 had refractory acquired SAA and 4
failed to engraft after UD (n¼ 3) or cord blood (n¼ 1) HSCT. Of the 3 patients
who had failed previous UDHSCT, 2 had failed 2 previous UD transplants. Six
of 8 patients had acquired idiopathic SAA. Two patients had secondary
severe marrow aplasia, 1 after chemotherapy for Hodgkin disease and who
subsequently failed UD HSCT and 1 who failed 2 UD HSCTs for myelodys-
plastic syndrome. Median age was 32 years (range, 19 to 57) and median
disease duration 46 months (range, 6 to 91). Family donors were siblings
(n ¼ 5), parents (n ¼ 2), and children (n ¼ 1), and HLA matching was 5/10
(n ¼ 6) and 6/10 (n ¼ 2). Five patients were included in the previously re-
ported multicenter series [20].
Conditioning regimen was ﬂudarabine 30 mg/m2 (days 6 to 2), CY
14.5 mg/kg (days 6 and 5), and total body irradiation 2 Gy (day 1).
Unmanipulated G-CSFemobilized PBSCs were infused at a median CD34þ
cell dose of 6. 2106/kg (range,1.8 to 8.3). GVHD prophylaxis was CY 50mg/
kg/d (days þ3 and þ4), tacrolimus for 9 months maintaining trough drug at
10 to 15 mg/L with tapering between 9 and 12 months, and mycophenolate
15 mg/kg until day þ35.
Median follow-up of survivors was 14.8 months (range, 7.2 to 44.4).
Median Karnofsky and HCT-comorbidity index scores were 80% (range, 50 to
90) and 3 (range, 0 to 5), respectively. Neutrophil and platelet engraftment
and acute and chronic GVHD were deﬁned as previously reported [21].
Chimerism was assessed in unfractionated BM and peripheral blood CD3þ
T cells and CD15þ granulocyte populations. Full donor chimerism was
deﬁned as >95% donor hematopoietic cells and mixed chimerism as 5% to
95% cells [21,22]. All patients were screened for cytomegalovirus, Epstein-
Barr virus, and adenovirus at twice weekly intervals for the ﬁrst 3 months.
HLA antibodies were measured routinely pretransplant in all patients using
microbead ﬂow cytometry assay with mean ﬂuorescence intensity read-out
for serum antibody level.
RESULTS
Six patients had sustained neutrophil engraftment; me-
dian time to neutrophil engraftment was 18.5 days (range, 16
to 23), and 5 sustained platelet engraftment with a median
time of 26 days (range, 21 to 27) (Table 1). Full donor
chimerism in unfractionated cells and CD3 and CD15 line-
ageswas achieved andmaintained at last follow-up (Table 2).
These results are different from the pattern of chimerism as
previously reported from our group using ﬂudarabine, CY,
alemtuzumab (FCC) conditioning regimen for SAA patients
transplanted from sibling or matched UDs, where a high
incidence of mixed T cell chimerism in the presence of full
donor myeloid chimerism was observed, associated with a
very low incidence of chronic GVHD [22]. We therefore
compared BM trephine cellularity at days þ28 and þ100 and
at 1 year after haploHSCTwith results using FCC conditioning
for sibling and UD HSCT from our center. As seen in
Supplementary Figure 1, the median BM cellularity at each
time point was not signiﬁcantly different between the 2
groups.
Two patients (patients 6 and 8) who failed to engraft died
on days þ60 and þ137 from sepsis. Both had multiple HLA
antibodies directed against the donor which persisted at high
level despite treatmentwith rituximab (375mg/m2weekly for
4 weeks) and plasma exchanges pretransplant (Figure 1A,B).
In contrast, sustained engraftment occurred in patients with
no HLA antibodies. For patient 6, there was a reduction in
the HLA-B51, donor-directed, antibody level, but despite this
the patient failed to engraft. The second patient with mul-
tiple donor-directed HLA antibodies achieved a signiﬁcantreduction in antibody levels for 3 antibodies but not for HLA-
DR53 speciﬁc antibody.
Cytomegalovirus and Epstein-Barr virus viremia occurred
in 2 and 5 patients, respectively, but no cases of cytomega-
lovirus disease or Epstein-Barr virus post-transplant lym-
phoproliferative disorder occurred. There was no adenovirus
viremia. One patient developed Guillain-Barré syndrome
(patient 2) with no viral pathogens identiﬁed. No response to
intravenous immunoglobulin occurred, but some improve-
ment was found with plasmapheresis. During this episode
the patient required a prolonged period of intubation during
a 92-day intensive care unit admission, which was compli-
cated by recurrent respiratory infections with multiple or-
ganisms. At the time of death he was independent of platelet
transfusions with the use of eltrombopag and required RBC
transfusion approximately 6 weekly.
There was only 1 case of acute GVHD (grade II skin) and
no chronic GVHD; however, follow-up was short, with a
median follow-up of patients of 12.2 months (range, 3.2 to
40.4). The conditioning regimen was well tolerated, with no
hemorrhagic cystitis. One patient (patient 3) delivered a
healthy baby at term on day þ560 post-transplant. The
observation that this regimen does not appear to cause
gonadal failure is supported by a previous report of 2 suc-
cessful pregnancies using this regimen [23].DISCUSSION
We show in a small cohort of patients with aplastic ane-
mia that haploHSCT using a uniform, nonmyeloablative
conditioning regimen with post-transplant CY and with
PBSCs as stem cell source rather than BM is a feasible option.
Remarkably, the procedure was able to rescue all 4 patients
who had primary graft failure after a matched UD transplant
or cord blood HSCT, including 2 patients with nonengraft-
ment after 2 unrelated grafts. Furthermore, our patients had
a high HCT-comorbidity index and poor performance status.
This series includes 2 patients with secondary aplasia, 1 due
to chemotherapy for Hodgkin lymphoma. Although the
mechanism underlying the marrow failure in these 2 cases is
different from those with idiopathic SAA, these cases also
illustrate the efﬁcacy of this approach after failed matched
UD or cord blood donor HSCT in the presence of severe
pancytopenia and a hypocellular BM.
In contrast to our previous ﬁnding of mixed T cell
chimerism with sustained myeloid engraftment using
alemtuzumab-based conditioning for matched sibling and
UD HSCT for SAA, in this study we observed sustained donor
T cell and myeloid engraftment in all assessable patients. We
used G-CSFemobilized stem cells in preference to BM cells to
optimize the infused stem cell dose for halpoHSCT. Stem cell
dose is especially important in SAA, where there is an inverse
correlation between stem cell dose and graft rejection [24].
The concernwith PBSCs of an increased risk of GVHDwas not
borne out in our small series. We previously reported a high
incidence of mixed T cell chimerism with sustained myeloid
engraftment and a low incidence of chronic GVHD in SAA
patients transplanted from matched sibling donors or UDs
using the FCC conditioning regimen [22]. In contrast, in this
study of haploHSCT, we showed full donor T cell and myeloid
chimerism in engrafted patients. We therefore were inter-
ested to know if hematopoietic recovery was associated with
a higher degree of BM cellularity after haploHSCT compared
with FCC HSCT. However, we showed no signiﬁcant differ-
ence between the 2 groups, but the patient numbers in the
Table 1
Patient Characteristics and Outcomes
Patient No., Age (yr),
Gender/Donor
Disease and Severity Previous Therapy for Aplasia
Pre-HaploHSCT
Previous HSCT and
Outcome
HCT-CI/
Karnofsky Score
CD34 Stem Cell
Dose (106/kg)
Engraftment (Neutrophil
and Platelet)
GVHD (Acute
and Chronic)
Median Follow-Up
(mo)/Survival Status
1, 19, F/mother SAA-MDS ATG þ CSA  2, NR
ATG þ MMF, PR, relapse
MMF-NR
Double cord-GF 0/80 6.7 Day þ18
Day þ21
None 40.4/alive
2, 51, M/sister Therapy-related severe
aplasia for Hodgkin disease
ATG þ CSA, NR MUD-GF 3/70 4.5 Day þ18
No platelet engraftment
None 22/dead
Sepsis
3, 23, F/sister SAA/hPNH ATG þ CSA, PR, relapse None 3/80 5.8 Day þ16
Day þ26
Grade II
acute GVHD
Skin
12.2/alive
4, 57, F/brother SAA/hPNH ATG þ CSA, CR, relapse,
oxymetholone, eculizumab
eltrombopag
MUD-GF
MUD-GF and
Epstein-Barr virus PTLD
5/50 4.9 Day þ20
Day þ27
None 9.3/alive
5, 22, M/brother VSAA ATG þ CSA, NR None 1/90 6.9 Day þ23
Day þ27
None 3.2/alive
6, 20, M/father VSAA CSA, NR
ATG þ MMF, NR
oxymetholone, NR
danazol, NR
None 1/90 6.7 Non-engraftment
HLA antibody positive
None 2.1/dead
Graft failure/sepsis
7, 50, M/son Therapy-related severe
aplasia for MDS-RCMD
None MUD-GF
MUD-GF
4/50 8.3 Day þ19
Day þ25
100%
None 33.4/alive
8, 41, M/mother VSAA/PNH ATG þ CSA  2, CR, relapse  2,
oxymetholone, PR, relapse,
eculizumab
None 5/80 1.8 Nonengraftment
HLA antibody positive
None 3.1/dead
HCT-CI indicates HCT comorbidity index; MDS, myelodysplastic syndrome; ATG, antithymocyte globulin; CSA, cyclosporine A; NR, no response; MMF, mycophenolate; PR, partial response; GF, graft failure; MUD, matched
unrelated donor; hPNH, hemolytic paroxysmal nocturnal hemoglobinuria; PTLD, post-transplant lymphoproliferative disease; VSAA, very severe aplastic anemia; RCMD, refractory cytopenia with multilineage dysplasia; CR,
complete response.
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Table 2
Results of Chimerism
Days Post-Transplant No. Patients Chimerism
Tested (Total Assessable)
UF (Range) CD3 (Range) CD15 (Range)
28 6 (8) 100 (99-100) 100 (100-100) 100 (98-100)
56 6 (7) 99 (98-100) 100 (99-100) 99 (98-100)
100 6 (6) 100 (99-100) 100 (99-100) 100 (99-100)
180 5 (6) 100 (96-100) 99 (96-99) 100 (96-100)
365 4 (4) 100 (99-100) 100 (99-100) 100 (100-100)
UF indicates unfractionated.
Values in the last 3 columns are median percentages.
J. Clay et al. / Biol Blood Marrow Transplant 20 (2014) 1711e17161714haploHSCT group were small, and more patients need to be
evaluated.
For both haplo and cord blood HSCT, the presence of
recipient HLA antibodies directed against the donor is asso-
ciated with a high risk of graft rejection [15,16]. Most studiesFigure 1. (A) Patient 6. Changes in HLA antibody levels as measured by the mean ﬂuo
the bottom. Before HSCT, this patient had multiple class I HLA antibodies, of which only
the antibody level fell from a peak of 7946 MFI to 1304 immediately pre-HSCT. PEX
measured by MFI. Recipient and donor HLA typing are shown in table at the bottom.
donor directed: HLA-B45, -DR7, -DQ2, and -DR53. (HLA-DR53 is directed against a pro
After plasma exchanges and before HSCT, there was a further rise in the HLA-DR53 antof haploHSCT for SAA do not report routine assessment of
donor-directed HLA antibodies. High levels of donor-directed
anti-HLA alloantibodies most likely explain the nonengraft-
ment in 2 patients. Intensive desensitization with plasma
exchanges and rituximab was insufﬁcient to deplete therescence index (MFI). Recipient and donor HLA typing are shown in the table at
HLA-B51 was donor directed. After intensive plasma exchanges and rituximab,
indicates plasma exchange. (B) Patient 8. Changes in HLA antibody levels as
Pretransplant, this patient had class I and II HLA antibodies, all of which were
tein encoded by the DRB4 gene, which is in a haplotype with the DRB1*07:01.)
ibody, likely due to granulocyte transfusions given for invasive fungal infection.
J. Clay et al. / Biol Blood Marrow Transplant 20 (2014) 1711e1716 1715antibodies sufﬁciently to prevent graft rejection. Despite
universal leucodepletion of blood products, HLA alloimmu-
nization remains a problem in up to 30% of patients with
aplastic anemia [25,26]. In the setting of HLAmatched sibling
HSCT, this is due to minor histocompatibility antigens on
leucocytes and red cell, and in mismatched HSCT, due to HLA
antigens on leucocytes and platelets [27]. An HLA antibody
level of 1500 mean ﬂuorescence intensity is associated with
graft rejection in the setting of T celledepleted haploHSCT
and >2500 in the setting of T celledepleted matched UD
HSCT due to anti-DPB1 HLA antibodies [28,29]. In our series,
for HLA-B51 and HLA-DR53, graft rejection occurred at levels
of 1304 and 7621, respectively. Other factors contributing to
graft rejection in patient 8 were older donor age (mother’s
age of 68 years) [30], a low stem cell dose (1.8  106
CD34 cells/kg), and a female multiparous donor [28]. It may
be that transplanting a much higher CD34 dose would aid
engraftment in such cases, but this would potentially in-
crease the risk of acute and chronic GVHD. Thus, for future
cases, we agree that routine screening for HLA antibodies is
essential pretransplant and, if present, as has been recom-
mended for patients with hematological malignancies, an
alternative donor lacking HLA antigen(s) against which
recipient HLA antibody (ies) are directed should be used [16].
PBSCs have also recently been used for reduced-intensity
haploHSCT with postgraft CY in the setting of hematologi-
cal malignancy with no adverse impact on GVHD or survival
compared with BM [20,31].
In our study of SAA we showed that haploHSCT using
postgraft high-dose CY and PBSCs results in sustained
engraftment and with minimal GVHD for those patients who
lack donor-directed HLA antibodies. However, the presence
of donor-directed HLA antibodies was associated with pri-
mary engraftment failure, despite attempts to remove the
antibodies pretransplant with rituximab and plasma ex-
change. Because SAA patients have a particularly high risk of
HLA alloimmunization, it is essential that all patients are
screened pre-HSCT before considering such an approach,
because the presence of donor-directed HLA antibodies
should preclude the use of that donor.
We propose that this approach to haploHSCT now war-
rants further exploration in a larger cohort of SAA patients.
The European Group for Blood and Marrow Transplantation
Severe Aplastic Anaemia Working Party has adopted this
protocol for a future noninterventional, observational pro-
spective study of haploHSCT throughout Europe.
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